Isofol Medical (ISOFOL) Q3 2024 earnings summary

Executive summary

• Preparing to launch a Phase Ib/II clinical study for arfolitixorin in colorectal cancer, with study start expected in Q1 2025 and design expanded to optimize dose-response and efficacy.

• Recent preclinical and post hoc analyses indicate higher doses of arfolitixorin may improve efficacy without compromising safety, forming the basis for the new study design.

• Positive preliminary patentability report received for a new international product patent application for arfolitixorin, potentially strengthening IP protection.

• No significant events occurred after the reporting period.

Financial highlights

• Net revenue was KSEK 0 for Q3 2024 (KSEK 0 in Q3 2023) and KSEK 0 for Jan–Sep 2024 (KSEK 721 in Jan–Sep 2023).

• Result for Q3 2024 was KSEK -10,859 (KSEK -6,245 in Q3 2023); for Jan–Sep 2024, KSEK -30,387 (KSEK -28,188 in Jan–Sep 2023).

• Earnings per share for Q3 2024 was SEK -0.07 (SEK -0.04); for Jan–Sep 2024, SEK -0.19 (SEK -0.17).

• Cash and cash equivalents at September 30, 2024, were KSEK 104,020 (KSEK 144,176 at September 30, 2023).

• No loans outstanding and no material investments planned or ongoing.

Outlook and guidance

• The upcoming clinical study is expected to start in Q1 2025, with a more comprehensive design to maximize the likelihood of positive results.

• Expanded study design and additional cohorts will increase costs and preparation time, but are justified by the evidence platform.

• If efficacy is confirmed, arfolitixorin could become a key innovation in first-line colorectal cancer treatment.